tbuckley/cabot-search huggingface dataset:
Can antisense oligonucleotides targeted K-<i>ras</i> gene downregulate the expression of MMP-2 and MMP-9 in orthotopically implanted pancreatic cancer in Syrian golden hamsters
Authors: C. Y. Morioka, F. P. Costa, S. Saito, E. M. Lima, A. Watanabe, C. C. Huang
Journal: Journal of Clinical Oncology (2007)

14147 Background: Matrix metalloproteinases (MMP), especially MMP-2 and MMP-9, are thought to play major roles in pancreatic cancer growth and metastasis.Ras activates a multitude of downstream activities with roles in cellular processing, including invasion and metastasis.Therefore, antisense oligonucleotides (ASO) targeting K-ras gene may be a therapeutic approach. Aim: To elucidate the effectiveness of this gene therapy in growth, invasiveness,and expression of MMPs,in hamster experimental pancreatic cancer model. Materials and Methods: HaP-T1,a cell line derived from BHP-induced pancreatic cancer was used.Transfection with ASO were performed.MTT and MTT agarose assays were performed.MMP-2 and MMP-9 production by HaP-T1 was determined by gelatin zymography.For in vivo experiments,subcutaneously resected tumors were implanted orthotopically in Syrian golden hamsters,which were divided in 3 groups:Positive control (PC),Sense treated hamsters (STH), and Antisense treated hamsters (ATH).Follow up was done.Animals of each group were sacrificed at Days 10,17,24,31,and 38,to study local response and metastatic sites.Survival time was studied. Specimens were studied histopathologically.Orthotopic pancreatic tumor MMP production was measured by gelatin zymography. Results: ASO inhibited the tumoral growth.They downregulated active forms of MMP-2 and MMP-9 in a dose dependent manner in vitro.PC,STH,and ATH survived in average 72.7, 74,3, and 82,7 days,respectively.Spontaneous lymph node metastases were found from 31 days in ATH group,while PC and STH groups showed metastases and direct invasion to adjacent organs from 17 days.After death,metastatic sites were similar in the 3 groups.ASO downregulated the activation of MMP-9, more than MMP-2 in vivo. Conclusions: ASO targeted K-ras gene suppressed tumor growth in vitro and in vivo.ASO also downregulated the activation of MMP-2 and MMP-9 in vitro.However, it downregulated more MMP-9 than MMP-2 in vivo.Nevertheless, it can be a good choice in management of pancreatic cancer because MMP play an important role in the process of metastasis. No significant financial relationships to disclose.
Predictors of Trachomatous Trichiasis Surgery Outcome
Authors: Esmael Habtamu, Tariku Wondie, Sintayehu Aweke, Zerihun Tadesse, Mulat Zerihun, Bizuayehu Gashaw, Guadie S. Wondimagegn, Hiwot D. Mengistie, Saul N. Rajak, Kelly Callahan, Helen A. Weiss, Matthew J. Burton
Journal: Ophthalmology (2017)

Unfavorable outcomes after trachomatous trichiasis (TT) surgery are undermining the global trachoma elimination effort. This analysis investigates predictors of postoperative TT (PTT), eyelid contour abnormalities (ECAs), and granuloma in the 2 most common TT surgery procedures: posterior lamellar tarsal rotation (PLTR) and bilamellar tarsal rotation (BLTR).Secondary data analysis from a randomized, controlled, single-masked clinical trial.A total of 1000 patients with TT, with lashes touching the eye or evidence of epilation, in association with tarsal conjunctival scarring.Participants were randomly allocated and received BLTR (n = 501) or PLTR (n = 499) surgery. Disease severity at baseline, surgical incisions, sutures, and corrections were graded during and immediately after surgery. Participants were examined at 6 and 12 months by assessors masked to allocation.Predictors of PTT, ECA, and granuloma.Data were available for 992 (99.2%) trial participants (496 in each arm). There was strong evidence that performing more peripheral dissection with scissors in PLTR (odd ratio [OR], 0.70; 95% confidence interval [CI], 0.54-0.91; P = 0.008) and BLTR (OR, 0.83; 95% CI, 0.72-0.96; P = 0.01) independently protected against PTT. Baseline major trichiasis and mixed location lashes and immediate postoperative central undercorrection independently predicted PTT in both surgical procedures. Peripheral lashes in PLTR (OR, 5.91; 95% CI, 1.48-23.5; P = 0.01) and external central incision height ≥4 mm in BLTR (OR, 2.89; 95% CI, 1.55-5.41; P = 0.001) were independently associated with PTT. Suture interval asymmetry of >2 mm (OR, 3.18; 95% CI, 1.31-7.70; P = 0.01) in PLTR and baseline conjunctival scarring in BLTR (OR, 1.72; 95% CI, 1.06-2.81; P = 0.03) were independently associated with ECA. Older age was independently associated with ECA in both PLTR (P value for trend < 0.0001) and BLTR (P value for trend = 0.03). There was substantial intersurgeon variability in ECA rates for both PLTR (range, 19.0%-36.2%) and BLTR (range, 6.1%-28.7%) procedures. In PLTR surgery, irregular posterior lamellar incision at the center of the eyelid (OR, 6.72; 95% CI, 1.55-29.04; P = 0.01) and ECA (OR, 3.08; 95% CI, 1.37-6.94; P = 0.007) resulted in granuloma formation.Poor postoperative outcomes in TT surgery were associated with inadequate peripheral dissection, irregular incision, asymmetric suture position and tension, inadequate correction, and lash location. Addressing these will improve TT surgical outcomes.
FDA Approval of Eteplirsen for Muscular Dystrophy—Reply
Authors: Aaron S. Kesselheim, Jerry Avorn
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCTAP A-077 Intracardiac Ultrasound Assistance Method in ASD Closure Procedure
Authors: Igor V. Buzaev, Vladimir V. Plechev, Irina E. Nikolaeva, Inna E. Yamanayeva, Eustaquio M. Onorato, Vladimir Anatolyevich Surkov
Journal: Journal of the American College of Cardiology (2017)
Contents Vol. 72, 2003
Authors: D Healy, M Fava, P Jacques, J Selhub, I Rosenberg, S Eisendrath, J Lichtmacher, E Haller, A Fleming, M Fritch, D Weiss, M Jacobs, S Hall, W Van Zelst, A Beekman
Journal: Psychotherapy and Psychosomatics (2003)
Molecular Pathways: Metabolic Control of Histone Methylation and Gene Expression in Cancer
Authors: Thai Q. Tran, Xazmin H. Lowman, Mei Kong
Journal: Clinical Cancer Research (2017)

Abstract Epigenetic alterations contribute to tumor development, progression, and therapeutic response. Many epigenetic enzymes use metabolic intermediates as cofactors to modify chromatin structure. Emerging evidence suggests that fluctuation in metabolite levels may regulate activities of these chromatin-modifying enzymes. Here, we summarize recent progress in understanding the cross-talk between metabolism and epigenetic control of gene expression in cancer. We focus on how metabolic changes, due to diet, genetic mutations, or tumor microenvironment, regulate histone methylation status and, consequently, affect gene expression profiles to promote tumorigenesis. Importantly, we also suggest some potential therapeutic approaches to target the oncogenic role of metabolic alterations and epigenetic modifications in cancer. Clin Cancer Res; 23(15); 4004–9. ©2017 AACR.
Abstract P130: Estrogen Receptor β Mediates the Rescue of Cardiac Function in Advanced Heart Failure by Promoting Neoangiogenesis and Reducing Fibrosis
Authors: Andrea Iorga, Rod Partow-Navid, Humann Matori, Jingyuan Li, Soban Umar, Mansoureh Eghbali
Journal: Circulation Research (2011)

Estrogen can act via the estrogen receptor alpha (ERa) or estrogen receptor beta (ERb) to exert its biological effects, and both of these receptors are present in the heart. We have previously shown that short-term estrogen (E2) treatment can rescue pressure overload-induced decompensated heart failure (HF) in mice, and that this rescue is achieved mainly through the ERb. Furthermore, E2 has been shown to regulate angiogenesis in different tissues. Because HF has been associated with decreased angiogenesis and increased fibrosis, here we investigated whether the E2-induced rescue of HF by the selective ERb agonist DPN can regulate cardiac fibrosis and neoangiogenesis. We used transaortic constriction to induce HF, and once the ejection fraction (EF) reached ∼30%, one group of animals was sacrificed (HF group), and the other three groups received either 17b-estradiol via a subcutaneous pellet implant (0.012mg/pellet, n=16), selective ERa agonist (PPT, 0.625mg/kg/day), or selective ERb agonist (DPN, 0.625mg/kg/day) for 10 days. Serial echocardiography was performed to monitor cardiac structure and function. As expected, E2 rescued HF by restoring EF from 33.17±1.12% to 53.05±1.29%. Mice treated with DPN had a significant EF improvement from 33.17±1.12% to 45.25±2.1% (n=7), while the EF of PPT-treated mice did not improve (31.09±2.3%, n=6). Similarly, only the fractional shortening of DPN-treated mice improved from 15.7±0.58% in HF to 21.95±1.65% with DPN treatment vs. 14.72±1.24% with PPT. Next, we examined whether promotion of cardiac neoangiogenesis and suppression of fibrosis by the selective ERb agonist are possible mechanisms in the rescue action of HF by DPN. DPN treatment was able to reverse the interstitial and perivascular fibrosis observed in HF, while PPT had no effect. The selective ERb agonist also stimulated neoangiogenesis, as the capillary density was increased from 0.46±0.04 microvessels/cardiomyocyte in HF to 0.67±0.07 with DPN treatment, whereas PPT treatment had no effect (0.43±0.03). Our data strongly suggests that upregulation of cardiac neoangiogenesis and reversal of fibrosis are pivotal mechanisms in rescuing advanced HF by the estrogen receptor beta agonist DPN.
Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer
Authors: Di Wen, Yang Peng, Feng Lin, Rakesh K. Singh, Ram I. Mahato
Journal: Cancer Research (2017)

Abstract Treatment of prostate cancer with paclitaxel often fails due to the development of chemoresistance caused by downregulation of the tumor suppressor gene miR-34a. In this study, we demonstrate that codelivery of paclitaxel and 2'-hydroxy-2,4,4',5,6'-pentamethoxychalcone (termed rubone) drives upregulation of miR-34a and chemosensitizes paclitaxel-resistant prostate cancer cells, killing both cancer stem–like cells (CSC) and bulk tumor cells. Rubone upregulated miR-34a and reversed its downstream target genes in DU145-TXR and PC3-TXR cells. Paclitaxel and rubone combination therapy inhibited tumor cell growth, migration, and CSC population growth. We synthesized poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol; PEG-PCD) to prepare micelles. The drug-loading capacities were 9.70% ± 0.10% and 5.34% ± 0.02% for paclitaxel and rubone, respectively, controlling a drug release of 60.20% ± 2.67% and 60.62% ± 4.35% release of paclitaxel and rubone at 24 hours. Delivery of miR-34a and rubone decreased PC3-TXR cell viability with increasing paclitaxel concentration. Coincubation with a miR-34a inhibitor diminished the effect of rubone. Paclitaxel IC50 in PC3 and PC3-TXR cells was 55.6 and 2,580 nmol/L, respectively, but decreased to 49.8 and 93.2 nmol/L when treated in combination with rubone, demonstrating a reversal of paclitaxel resistance by rubone. Systemic administration of micelles carrying paclitaxel and rubone inhibited orthotopic prostate tumor growth in nude mice, compared with monotherapy, by reversing the expression of miR-34a, SIRT1, cyclin D1, and E-cadherin. In summary, our results showed how rubone acts as an efficient small-molecule modulator of miR-34a to reverse chemoresistance and further enhance the therapeutic efficacy of paclitaxel in paclitaxel-resistant prostate cancer. Cancer Res; 77(12); 3244–54. ©2017 AACR.
Indian surgeons call for end to unnecessary operations in private sector
Authors: Sumi S Dutta
Journal: BMJ (2017)

A panel of surgeons in India has called on professional surgical societies to tackle the twin problems of unethical surgical practices in the private healthcare sector and the lack of services for vast numbers of the population.

The panel members, speaking at the release of The BMJ ’s Health in South Asia supplement last week (www.bmj.com/health-in-south-asia), appealed to surgical societies to make efforts to reduce “healthcare corruption” in private hospitals, and to collaborate with the government to reduce inequitable access to surgical care.

Surveys of health facilities show a severe lack of surgical resources at referral hospitals. India’s community health centres, which serve rural populations across the country, have only 896 surgeons against a …
3D Morphological Changes in LV and RV During LVAD Ramp Studies
Authors: Karima Addetia, Nir Uriel, Francesco Maffessanti, Gabriel Sayer, Sirtaz Adatya, Gene H. Kim, Nitasha Sarswat, Savitri Fedson, Diego Medvedofsky, Eric Kruse, Keith Collins, Daniel Rodgers, Takayoshi Ota, Valluvan Jeevanandam, Victor Mor-Avi, Daniel Burkhoff, Roberto M. Lang
Journal: JACC. Cardiovascular imaging (2017)
Y- BALANCE TEST SCORE COMPARISON BETWEEN PRE-SEASON AND IN-SEASON IN YOUTH ATHLETES
Authors: Natalia Bittencourt, Marcela Leite, Leandro Garcia, Luciana Mendonça, Ana Carolina Bithencourt, Gabriela Gonçalves
Journal: British Journal of Sports Medicine (2017)

Background The Y-balance test has been used clinically to assess neuromuscular control deficits and a composite score of &lt;94% and anterior asymmetry of &gt;4 cm have been associated with lower limb injuries in basketball athletes. Objective To compare Y-test performance during the pre-season to in-season in injury-free athletes. Design Prospective study. Setting Brazilian sports club, mixed sports. Patients (or Participants) 182 injury-free youth athletes (145 male and 37 female) from judo, volleyball, basketball, gymnastics and indoor soccer were assessed (age 14.3±2.8; height 168±19 cm, body mass 60±18 kg). Assessment of Risk Factors The Y-test was assessed during the pre-season (February) and in-season (June). Athletes practiced 6 trials on each leg prior to formal testing. While maintaining single-leg stance, they were asked to reach with the free limb in the anterior, posteromedial, and posterolateral directions. Main Outcome Measurements Y-test performance was calculated as the composite score (sum of the three reach distances, divided by 3 times limb length, then multiplied by 100). Anterior distance asymmetry was calculated as the difference between the dominant limb (DL) and non-dominant limb (NDL) values. Both measures were compared between pre- and in-season. Results The pre-season average composite score for DL was 87.5% and for NDL 87.8%, while the average anterior distance asymmetry was 3.7 cm. During in-season, the average composite score was 85.4% for DL and NDL, and the anterior distance asymmetry was 3.0 cm. T-tests revealed statistically significant differences for the composite score (p&lt;0.001) and for anterior distance asymmetry (p=0.01). Conclusions Athletes showed poorer composite score values during in-season compared to pre-season and the values were below the risk cut-off point reported in the literature. This group did not present substantial anterior distance asymmetry .
The place of periodontal examination and referral in general medicine
Authors: Samuel Chan, Graham M. Pasternak, Malcolm J. West
Journal: Periodontology 2000 (2017)

Abstract In many countries, dental services, unlike other health‐care services, are not covered by the principle of universal access. It is only in the last couple of decades that there has been a greater interaction between medicine and dentistry. Various health‐care systems worldwide may provide public dental services to the young and the disadvantaged, but few provide access to all. Public policy does not appear to appreciate the vast economic, health and social implications of poor oral health on the overall health of an individual. Recognizing and acting on the interrelatedness between oral health and overall health helps to protect patients from pathological diseases, such as infective endocarditis, suboptimal glycemic control and deterioration in renal function. This review article examines some of the medical conditions to which patients are predisposed as a result of poor dental care. Additionally, the paper provides some real‐life case examples to support this hypothesis, reinforces the importance of a strong relationship that needs to be embedded between the dentist and the physician and finally provides some suggestions for a multidisciplinary approach.
TCTAP C-020 Treatment of AMI in the LCx Basin and AMI LAD Caused by Translocation of the Left Circumflex Thrombus Followed by PCI of the LAD During the Same Hospitalization for Detection of Silent Myocardial Ischemia
Authors: Alexey Biryukov, Kirill Alexeevich Smirnov, Dmitriy Vladimirovich Ovcharenko, Ekaterina Leonidovna Zaslavskaya, Andrei Aleksandrovich Voronkov
Journal: Journal of the American College of Cardiology (2017)
NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma
Authors: M Hao, R Franqui-Machin, H Xu, J Shaughnessy, B Barlogie, D Roodman, D E Quelle, S Janz, M H Tomasson, R D Sanderson, L Qiu, I Frech, G Tricot, F Zhan
Journal: Leukemia (2017)

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma
Activation of the LMO2 Oncogene in T-ALL through a Somatically Acquired Neomorphic Promoter
Authors: Sunniyat Rahman, Michael Magnussen, Theresa E. León, Nadine Farah, Brian J. Abraham, Zhaodong Li, Krisztina Z. Alapi, Rachel J. Mitchell, Tom Naughton, Adele K. Fielding, Arnold Pizzey, Sophia Bustraan, Christopher Allen, Rosemary E. Gale, David C. Linch, Richard A. Young, A. Thomas Look, Marc R Mansour
Journal: Blood (2016)
Secondary Central Nervous System Involvement with Concurrent Diffuse Large B Cell Lymphoma at Initial Presentation or at Relapse Is Associated with Zero Survival- a Decade's Experience from a Single Centre in Riyadh, Saudi Arabia
Authors: Imran K Tailor, Taimoor Hussain, Wafa Shakweer, Ghulam Murtaza, Ibraheem H Motabi, Syed Ziauddin A. Zaidi, Nawal F Shehry, Yasser Bayoumi, Mubarak S. AlGhamdi
Journal: Blood (2016)
Performing Percutaneous Coronary Intervention Without On-Site Cardiac Surgery Is Not a License for Percutaneous Coronary Intervention Instead of Coronary Artery Bypass Grafting—Reply
Authors: Kashish Goel, Tanush Gupta, Charanjit S. Rihal
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
Authors: Joel C. Sunshine, Peter L. Nguyen, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry, Jessica Esandrio, Haiying Xu, Aleksandra Ogurtsova, Karen B. Bleich, Toby C. Cornish, Evan J. Lipson, Robert A. Anders, Janis M. Taube
Journal: Clinical Cancer Research (2017)

Purpose: PD-L1 expression in the pretreatment tumor microenvironment enriches for response to anti-PD-1/PD-L1 therapies. The purpose of this study was to quantitatively compare the performance of five monoclonal anti-PD-L1 antibodies used in recent landmark publications.Experimental Design: PD-L1 IHC was performed on 34 formalin-fixed paraffin-embedded archival melanoma samples using the 5H1, SP142, 28-8, 22C3, and SP263 clones. The percentage of total cells (including melanocytes and immune cells) demonstrating cell surface PD-L1 staining, as well as intensity measurements/H-scores, were assessed for each melanoma specimen using a computer-assisted platform. Staining properties were compared between antibodies.Results: Strong correlations were observed between the percentage of PD-L1(+) cells across all clones studied (R2 = 0.81-0.96). When present, discordant results were attributable to geographic heterogeneity of the melanoma tissue section rather than differences in PD-L1 antibody staining characteristics. PD-L1 intensity/H-scores strongly correlated with percentage of PD-L1(+) cells (R2 > 0.78, all clones).Conclusions: The 5H1, SP142, 28-8, 22C3, and SP263 clones all demonstrated similar performance characteristics when used in a standardized IHC assay on melanoma specimens. Reported differences in PD-L1 IHC assays using these antibodies are thus most likely due to assay characteristics beyond the antibody itself. Our findings also argue against the inclusion of an intensity/H-score in chromogenic PD-L1 IHC assays. Clin Cancer Res; 23(16); 4938-44. ©2017 AACR.
Efficacy of the fissureless technique on decreasing the incidence of prolonged air leak after pulmonary lobectomy: A systematic review and meta-analysis
Authors: Shuang-Jiang Li, Kun Zhou, Yong-Jiang Li, Peng-Fei Li, Yan-Ming Wu, Lun-Xu Liu, Guo-Wei Che
Journal: International Journal of Surgery (2017)
Coagulation Testing in a Bleeding Patient
Authors: Michael Fralick, Michelle Sholzberg
Journal: JAMA (2017)

To the Editor The Diagnostic Test Interpretation by Dr Choi and colleagues1 highlighted 3 topics that deserve further discussion: (1) utility of routine coagulation testing; (2) limitations of a mixing study; and (3) appropriateness of a thrombophilia evaluation in a bleeding patient.